about
Emerging roles for intersectin (ITSN) in regulating signaling and disease pathwaysPhosphatidylinositol 3-kinase, class 2 beta (PI3KC2β) isoform contributes to neuroblastoma tumorigenesisUCR1C is a novel activator of phosphodiesterase 4 (PDE4) long isoforms and attenuates cardiomyocyte hypertrophy.Cooperative role of caveolin-1 and C-terminal Src kinase binding protein in C-terminal Src kinase-mediated negative regulation of c-Src.Protein Kinase A (PKA) Phosphorylation of Shp2 Protein Inhibits Its Phosphatase Activity and Modulates Ligand SpecificityIntersectin 1 contributes to phenotypes in vivo: implications for Down's syndrome.Changing Paradigms in Down Syndrome: The First International Conference of the Trisomy 21 Research Society.Inhibition of RAS function through targeting an allosteric regulatory site.Receptor tyrosine kinase ubiquitylation involves the dynamic regulation of Cbl-Spry2 by intersectin 1 and the Shp2 tyrosine phosphatase.Intersectin scaffold proteins and their role in cell signaling and endocytosis.Down syndrome: genes, model systems, and progress towards pharmacotherapies and clinical trials for cognitive deficits.Akt2 Stabilizes ATP7A, a Copper Transporter for SOD3 (Extracellular Superoxide Dismutase), in Vascular Smooth Muscles: Novel Mechanism to Limit Endothelial Dysfunction in Type 2 Diabetes Mellitus.Silencing Intersectin 1 Slows Orthotopic Neuroblastoma Growth in Mice.Targeting the α4-α5 interface of RAS results in multiple levels of inhibition.Direct inhibition of RAS: Quest for the Holy Grail?Pharmacological targeting of RAS: Recent success with direct inhibitorsTargeting the α4-α5 dimerization interface of K-RAS inhibits tumor formation in vivoTherapeutic targeting of RAS: New hope for drugging the "undruggable"Correction: Targeting the α4-α5 dimerization interface of K-RAS inhibits tumor formation in vivo
P50
Q26824407-A81C6B7A-CCF9-4925-82AA-B5AB6E68271FQ35153937-73800990-C5E6-40A3-9EF4-3FD7E24C4183Q35181565-D3577187-5FF1-4BBF-8FE9-77F65CC4D46CQ35275235-E359FD28-6BE3-4DFE-9D35-4F33E0B62D76Q35583091-6F0B7374-07F2-4DE0-B208-58D120A67ED3Q35921272-838D5A2A-6118-483B-B85D-AEEDA4408D6BQ37415153-C3AA1220-072E-4B01-A31A-6BE74A5806D3Q37540897-3ABA04F4-315B-4214-B947-59A339E1E664Q37546051-D9DB8755-A710-4E3B-A966-C63BF4397860Q38981976-FF14B87D-8CEA-4612-AD7A-04FBF42A0313Q46531220-7B244FB3-5FFF-42E5-81EE-8EDB1438DD79Q47231558-F153122B-5387-4BFA-AE44-C6FB63A644ABQ47978765-C1CD3C09-DE26-4357-85CA-48DDCB7D4F0AQ48151533-35FF0650-CC74-411E-A14F-0C0FB15BE67DQ49721819-F77D549B-52C8-4181-B921-8477AE558194Q58577211-398634C7-7B74-46D2-BCB9-BA43E51AD884Q90681757-7EA03FAB-0F26-4652-ACB0-A82403B698D2Q91069441-7EB3E41B-689F-492C-9A99-CF30A98F064EQ91312624-8D0D3038-8B04-4EE6-839A-F0BB10F4A497
P50
description
investigador
@es
researcher
@en
name
John P O'Bryan
@en
type
label
John P O'Bryan
@en
prefLabel
John P O'Bryan
@en
P31
P496
0000-0001-5386-1080